Zobrazeno 1 - 10
of 141
pro vyhledávání: '"R. Thurau"'
Autor:
Maria Diedrichs-Möhring, Sandy Niesik, Claudia S. Priglinger, Stephan R. Thurau, Franz Obermayr, Stefan Sperl, Gerhild Wildner
Publikováno v:
Journal of Neuroinflammation, Vol 15, Iss 1, Pp 1-11 (2018)
Abstract Background Uveitis is a potentially blinding inflammatory disease of the inner eye with a high unmet need for new therapeutic interventions. Here, we wanted to investigate the suppressive effect of the intraocular application of the small mo
Externí odkaz:
https://doaj.org/article/35027cc6f0494c0a811224b2e45aa2f2
Autor:
S. Tapio, Gerhild Wildner, Stephan R. Thurau, Kristian Unger, Florian Wagner, Andreas Beyerlein, Jochen Graw, Claudia Dalke, Horst Zitzelsberger, Ute Rößler, Fabian J. Theis, Jerzy Adamski, Andreas Ohlmann, Sarah Kunze, Gabriele Möller, Cornelia Prehn, Sabine M. Hölter, Ulrike Kulka, Alexander Cecil
Publikováno v:
Int. J. Radiat. Biol. 97, 529-540 (2021)
PURPOSE: The long-term effect of low and moderate doses of ionizing radiation on the lens is still a matter of debate and needs to be evaluated in more detail. MATERIAL AND METHODS: We conducted a detailed histological analysis of eyes from B6C3F1 mi
Autor:
Nora Aszodi, Andreas Wollenberg, Stephan R. Thurau, Marlene Seegräber, Marjolein S. de Bruin-Weller
Publikováno v:
JDDG: Journal der Deutschen Dermatologischen Gesellschaft. 17:488-492
Der monoklonale Antikorper Dupilumab (Dupixent® ) ist seit September 2017 in der EU als neue systemische Therapie bei mittelschwerem bis schwerem atopischem Ekzem zugelassen. Eine Unterdruckung der IL-4- und IL-13-Signalwege durch die Anwendung von
Autor:
Marinella Russo, Pia Allegri, Jeany Q. Li, Eline Whist, Elena Bolletta, Arnd Heiligenhaus, Gertrud Haas, Elisabetta Miserocchi, Gerhild Wildner, Barbara Teuchner, Hendrik Engelke, Luca Cimino, Richard Symes, Stephan R. Thurau, Peter McCluskey
Publikováno v:
Ocular immunology and inflammation. 30(7-8)
Purpose: New tumor therapies like immune checkpoint inhibitors and small molecule inhibitors of MEK and BRAF have increased the patient's survival rate but can be burdened with severe side-effects including uveitis. Here, we show the spectrum, treatm
Autor:
Irena Tsui, Claudia B. Catarino, Piero Barboni, Günther Rudolph, Nancy J. Newman, Sara Silvestri, Alfredo A. Sadun, Michael Dattilo, Neringa Jurkute, Jean-François Girmens, Cosima Schertler, Magali Taiel, Rustum Karanjia, Claudia Priglinger, Maria K Gemenetzi, Armin Wolf, Manuela Contin, Jasmina Al-Tamami, Thomas Klopstock, James Acheson, Robert C. Sergott, Deborah Gibbs, Rabih Hage, Stephan R. Thurau, Adam A. DeBusk, Lidia Di Vito, Mark L. Moster, Valérie Biousse, Med Lindreth DuBois, Valerio Carelli, Gad Heilweil, Chiara La Morgia, Michele Carbonelli, Andrew Hendrick, Patrick Yu-Wai-Man, Jason H. Peragallo, Gerard Smits, Angelika Pressler, Martin Hildebrandt, Alcides Fernandes Filho, Michael Neuenhahn, Bettina von Livonius, Barrett Katz, Daniel R Muth, Siegfried G. Priglinger, Lauren Leitch-Devlin, Susan Mohamed, William R. Tucker, Maria Massini, Maria Eleftheriadou, Laure Blouin, Catherine Vignal-Clermont, Eman Hawy, Simona Degli Esposti, Heather Tollis, G. Baker Hubbard, Jannah Rutter Dobbs, José-Alain Sahel, Catherine Vignal, Melissa SantaMaria, Julie A. Haller
Publikováno v:
Ophthalmology: Journal of The American Academy of Ophthalmology
Ophthalmology: Journal of The American Academy of Ophthalmology, Elsevier, 2021, 128 (5), pp.649-660. ⟨10.1016/j.ophtha.2020.12.012⟩
Ophthalmology 128(5), 649-660 (2021). doi:10.1016/j.ophtha.2020.12.012
Ophthalmology: Journal of The American Academy of Ophthalmology, Elsevier, 2021, 128 (5), pp.649-660. ⟨10.1016/j.ophtha.2020.12.012⟩
Ophthalmology 128(5), 649-660 (2021). doi:10.1016/j.ophtha.2020.12.012
International audience; Purpose: To evaluate the efficacy of a single intravitreal injection of rAAV2/2-ND4 in subjects with visual loss from Leber hereditary optic neuropathy (LHON).Design: RESCUE is a multicenter, randomized, double-masked, sham-co
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61639fdbd5cf15223e6676350bc8de96
https://hal.sorbonne-universite.fr/hal-03238444/file/1-s2.0-S0161642020311878-main.pdf
https://hal.sorbonne-universite.fr/hal-03238444/file/1-s2.0-S0161642020311878-main.pdf
Autor:
Christina V Miller, Annemarie Klingenstein, Elisabeth M. Messmer, Claudia Priglinger, Mehdi Shajari, Jakob Siedlecki, Raffael Liegl, Denise Vogt, Theresia Ring-Mangold, Wolfgang J. Mayer, Christoph Hirneiß, Bettina von Livonius, Martin Dirisamer, Efstathios Vounotrypidis, Thomas C. Kreutzer, Christoph Hintschich, Aylin Garip-Kübler, Nikolaus Luft, Armin Wolf, Marc J. Mackert, Günther Rudolph, Siegfried G. Priglinger, Oliver Ehrt, Michael Czihal, Tina Herold, Stephan R. Thurau
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::39e037448081f682504d10411b1b6792
https://doi.org/10.1055/b-006-149540
https://doi.org/10.1055/b-006-149540
Publikováno v:
International Journal of Ophthalmology, Vol 13, Iss 3, Pp 520-522 (2020)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5493c2db21426706854bb7ea8708a4c1
https://europepmc.org/articles/PMC7154204/
https://europepmc.org/articles/PMC7154204/
Autor:
Cornelia A. Deeg, Albert J. Raith, Barbara Amann, John W. Crabb, Stephan R. Thurau, Stefanie M. Hauck, Marius Ueffing, Gerhild Wildner, Manfred Stangassinger
Publikováno v:
Clinical and Developmental Immunology, Vol 2007 (2007)
Cellular retinaldehyde binding protein (CRALBP) is an autoantigen in spontaneous equine recurrent uveitis. In order to test whether CRALBP contributes to human autoimmune uveitis, the specificity of antibodies from human uveitis patient's sera was fi
Externí odkaz:
https://doaj.org/article/f26d3cc46a6048d3b379760d184ae32f
Autor:
Naveed Shams, Christine Fardeau, Shigeaki Ohno, Alay S. Banker, Sivakumar R. Rathinam, Phuc LeHoang, Abu Abraham, Yang Yang, Pauline T. Merrill, Stephan R. Thurau, Pablo Franco, Laura Wilson, W. Lloyd Clark, Quan Dong Nguyen
Publikováno v:
Ophthalmology. 123(11):2413-2423
Purpose To evaluate the efficacy and safety of intravitreal sirolimus in the treatment of noninfectious uveitis (NIU) of the posterior segment (i.e., posterior, intermediate, or panuveitis). Design Phase III, randomized, double-masked, active-control
Publikováno v:
Ocular Immunology and Inflammation. 25:122-133
Purpose: To explore the unmet needs in the management of patients with severe inflammatory eye disease (IED), future directions for research and therapy, and to develop and facilitate access and delivery of better medical care to patients with severe